Financial Survey: Bitdeer Technologies Group (NASDAQ:BTDR) versus Coeptis Therapeutics (NASDAQ:ZSQR)

Coeptis Therapeutics (NASDAQ:ZSQR – Get Free Report) and Bitdeer Technologies Group (NASDAQ:BTDR – Get Free Report) are both small-cap technology companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Profitability

This table compares Coeptis Therapeutics and Bitdeer Technologies Group’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Coeptis Therapeutics -773.72% -49.45% -46.88%
Bitdeer Technologies Group -31.84% -32.77% -9.29%

Valuation and Earnings

This table compares Coeptis Therapeutics and Bitdeer Technologies Group”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Coeptis Therapeutics $1.36 million 67.61 -$11.92 million ($1.63) -1.06
Bitdeer Technologies Group $620.25 million 1.07 $65.60 million ($2.24) -1.31

Bitdeer Technologies Group has higher revenue and earnings than Coeptis Therapeutics. Bitdeer Technologies Group is trading at a lower price-to-earnings ratio than Coeptis Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Coeptis Therapeutics and Bitdeer Technologies Group, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Coeptis Therapeutics 1 0 0 0 1.00
Bitdeer Technologies Group 1 2 11 0 2.71

Bitdeer Technologies Group has a consensus price target of $20.55, suggesting a potential upside of 602.41%. Given Bitdeer Technologies Group’s stronger consensus rating and higher possible upside, analysts plainly believe Bitdeer Technologies Group is more favorable than Coeptis Therapeutics.

Insider and Institutional Ownership

13.9% of Coeptis Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Bitdeer Technologies Group shares are owned by institutional investors. 24.2% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Coeptis Therapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the S&P 500. Comparatively, Bitdeer Technologies Group has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.

Summary

Bitdeer Technologies Group beats Coeptis Therapeutics on 10 of the 14 factors compared between the two stocks.

About Coeptis Therapeutics

(Get Free Report)

Coeptis Therapeutics was a biotechnology company focused on developing cell-based immunotherapies for cancer and other serious diseases. Its research centered on engineered immune cells, including CAR T-cell approaches designed to help the immune system recognize and attack diseased cells. The company’s development programs included therapies targeting blood cancers, as well as cell-therapy technologies intended to support broader treatment applications. These programs were investigational; Coeptis’s work focused on research and development rather than a portfolio of established, marketed medicines.

About Bitdeer Technologies Group

(Get Free Report)

Bitdeer Technologies Group is a technology company focused on cryptocurrency mining and related infrastructure. Its business includes operating mining data centers, mining digital assets for its own account, and providing hosting services that allow customers to deploy and operate mining equipment. The company also develops and sells cryptocurrency mining machines and offers cloud hash rate services, which provide customers access to computing capacity for mining without requiring them to operate the equipment themselves.

Receive News & Ratings for Coeptis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coeptis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.